View Future GrowthIIOT-OXYS 과거 순이익 실적과거 기준 점검 0/6IIOT-OXYS은 연평균 15%의 비율로 수입이 증가해 온 반면, Software 산업은 연평균 24.9%의 비율로 증가했습니다. 매출은 연평균 4%의 비율로 감소했습니다.핵심 정보15.00%순이익 성장률49.63%주당순이익(EPS) 성장률Software 산업 성장률17.33%매출 성장률-4.02%자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2026, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2026, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Mar 22IIOT-OXYS, Inc. announced that it expects to receive $0.21 million in funding from GHS Investments, LLCIIOT-OXYS, Inc. entered into a Securities Purchase Agreement with returning investor GHS Investments, LLC in the amount of up to $210,000 on MArch 21, 2025. The SPA provides for GHS’s purchase, from time to time, of up to 210 shares of the Company’s newly-designated Series D Convertible Preferred Stock (the “ Preferred Stock ”). The initial closing under the SPA consisted of 60 shares of Preferred Stock, stated value $1,200 per share, issued to GHS for an initial purchase price of $60,000, or $1,000 per share. At GHS and the Company’s option, and subject to the terms of the SPA and the Certificate of Designation for the Preferred Stock (the “ COD ”), additional closings in the aggregate amount of up to 150 shares of Preferred Stock for a total aggregate purchase price of up to $150,000 may take place.공시 • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/16/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 04/01/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Jun 16IIOT-OXYS, Inc. Appoints William D'Agostino to its Advisory BoardIIOT-OXYS, Inc. announced the appointment of William D'Agostino to its Advisory Board as a Technical Sales Consultant for his expertise in Biotechnology and Pharmaceutical Continuous Manufacturing Processes.공시 • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2023, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 01IIOT-OXYS, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 , First Quarter and Full Year of 2023IIOT-OXYS, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2022, first quarter and full year of 2023. As predicted, the fourth quarter revenue exceeded that in the third quarter. Overall, 2022 annual revenue exceeded that of 2020 and 2021 combined.This first quarter of 2023 is already on track to exceed the fourth quarter revenue in 2022. Overall, The company expects 2023 revenue to exceed that in 2022.공시 • Dec 06IIOT-OXYS, Inc. announced that it has received $0.061 million in fundingOn December 5, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. J.H. Darbie & Co., Inc. acted as a finder in the transaction. The company has paid $1,220 as finder fee in the transaction.공시 • Nov 25IIOT-OXYS, Inc. Provides Revenue Guidance for the Second Half and Full Year 2022IIOT-OXYS, Inc. provided revenue guidance for the second half and full year 2022. The company expected revenue for the second half of 2022 will exceed that generated in the first half of 2022.In total, the company expected that total revenue for 2022 will be approaching 2019 levels.공시 • Jul 13IIOT-OXYS, Inc. announced that it has received $0.027273 million in fundingOn July 12, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $546 to the finder J.H. Darbie & Co.공시 • Jun 24IIOT-OXYS, Inc. announced that it has received $0.030144 million in fundingOn June 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $603 to the finder J.H. Darbie & Co.공시 • Jun 09+ 2 more updatesIIOT-OXYS, Inc. Announces CFO ChangesIIOT-OXYS, Inc. announced that on June 2, 2022, Clifford L. Emmons resigned as Interim Chief Financial Officer and, on the same date, Karen McNemar, age 53, was appointed as the Interim Chief Financial Officer (Principal Financial and Accounting Officer) of the Company. Except as mentioned herein, there are no other arrangements or understandings between Ms. McNemar and any other persons pursuant to which Ms. McNemar was selected in the officer position above. There are no family relationships between Ms. McNemar and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. Ms. McNemar has served as Chief Operating Officer since September 20, 2018. From 1998 until August 2017, Ms. McNemar served in many capacities for Medtronic which included as a Senior Director of R&D Operations. Ms. McNemar is a collaborative strategic global business leader with extensive experience in New Product Development and Operations, building strong and effective diverse teams across organizations at all levels. Ms. McNemar is also a trusted advisor, recognized for successful process and program management, with a focus on leading complex initiatives and analyzing data and processes to identify solutions to increase organizational productivity and performance. Ms. McNemar received her Bachelor of Science in Industrial Engineering and Operations Research.공시 • May 24IIOT-OXYS, Inc. announced that it has received $0.043096 million in fundingOn May 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $4,310 to the finder J.H. Darbie & Co.공시 • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2022, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Feb 26IIOT-OXYS, Inc. announced that it has received $0.051 million in fundingOn February 24, 2022, IIOT-OXYS, Inc. closed the transaction. The company has received funding from one investor.공시 • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2021, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Mar 18IIOT-OXYS, Inc. Appoints Chandran Seshagiri as Company's Advisory Board ChairmanIIOT-OXYS, Inc. announced the appointment of Chandran Seshagiri as the company's Advisory Board Chairman. Chandran is uniquely qualified to lead company Advisory Board, as he has made significant contributions to company past successful projects and continues to lead company algorithm development efforts on current and future projects. His passion for transforming complex signals into actionable information began with his work at the Harvard-MIT Division of Health Sciences and Technology, where he completed his Ph.D. Chandran's work analyzing physiological time series signals to enable personalized delivery of anesthesia as well as neurostimulation therapy has translated well to the time series data and predictive analyses required for Smart Manufacturing and Structural Health Monitoring applications for IIOT-OXYS, Inc.'s customers.공시 • Sep 28IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc.IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc. on September 26, 2019. The closing of the transaction is subject to a number of conditions precedent, including satisfactory due diligence and the execution of definitive agreements, including employment agreements with the principal officers and directors of Infinite Automation Systems.공시 • Sep 26IIOT-OXYS, Inc. announced that it expects to receive $0.5 million in funding from Catalytic Capital, LLC and another investorIIOT-OXYS, Inc. (OTCPK:ITOX) announced that it has entered into a securities purchased agreement for the private placement of 12% senior secured convertible notes for gross proceeds of $500,000 on March 6, 2019. The note is convertible, in whole or in part, into common shares at a conversion price of $0.20 per share. The note bears interest at a rate of 12% per annum payable quarterly. The will note matures on March 1, 2021. The notes will be issued in 3 tranches of $100,000 and last tranche of $200,000. The company will issue warrants to purchase one share of the company for 50% of the number of shares of shares issuable upon conversion of the note. Each warrant is immediately exercisable at $0.30 per share and expires five years from the issuance date. The notes will be issued pursuant to exemption provided under Regulation D. On the same date, the company has received $100,000 from Catalytic Capital, LLC and YVSGRAMORAH LLC for $50,000 each in its first tranche. The company also issued 250,000 warrants in the tranche.공시 • Aug 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/17/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 30IIOT-OXYS, Inc. announced delayed 10-Q filingOn 06/29/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.매출 및 비용 세부 내역IIOT-OXYS가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:ITOX 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-10030 Sep 250-10030 Jun 25000031 Mar 250-10031 Dec 240-10030 Sep 240-11030 Jun 240-11031 Mar 240-11031 Dec 230-11030 Sep 230-11030 Jun 230-11031 Mar 230-11031 Dec 220-11030 Sep 220-11030 Jun 220-11031 Mar 220-11031 Dec 210-11030 Sep 210-21030 Jun 210-21031 Mar 210-21031 Dec 200-21030 Sep 200-21030 Jun 200-21031 Mar 200-22031 Dec 190-22030 Sep 190-22030 Jun 190-22031 Mar 190-22031 Dec 180-21030 Sep 180-22030 Jun 180-22031 Mar 180-22031 Dec 170-220양질의 수익: ITOX 은(는) 현재 수익성이 없습니다.이익 마진 증가: ITOX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ITOX는 수익성이 없지만 지난 5년 동안 연평균 15%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ITOX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ITOX은 수익성이 없어 지난 해 수익 성장률을 Software 업계(14.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ITOX의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YSoftware 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/01 01:57종가2026/07/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스IIOT-OXYS, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2026, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2026, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2025, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Mar 22IIOT-OXYS, Inc. announced that it expects to receive $0.21 million in funding from GHS Investments, LLCIIOT-OXYS, Inc. entered into a Securities Purchase Agreement with returning investor GHS Investments, LLC in the amount of up to $210,000 on MArch 21, 2025. The SPA provides for GHS’s purchase, from time to time, of up to 210 shares of the Company’s newly-designated Series D Convertible Preferred Stock (the “ Preferred Stock ”). The initial closing under the SPA consisted of 60 shares of Preferred Stock, stated value $1,200 per share, issued to GHS for an initial purchase price of $60,000, or $1,000 per share. At GHS and the Company’s option, and subject to the terms of the SPA and the Certificate of Designation for the Preferred Stock (the “ COD ”), additional closings in the aggregate amount of up to 150 shares of Preferred Stock for a total aggregate purchase price of up to $150,000 may take place.
공시 • Nov 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 11/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 15IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/14/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/16/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 04/01/2024, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Jun 16IIOT-OXYS, Inc. Appoints William D'Agostino to its Advisory BoardIIOT-OXYS, Inc. announced the appointment of William D'Agostino to its Advisory Board as a Technical Sales Consultant for his expertise in Biotechnology and Pharmaceutical Continuous Manufacturing Processes.
공시 • May 16IIOT-OXYS, Inc. announced delayed 10-Q filingOn 05/15/2023, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 01IIOT-OXYS, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 , First Quarter and Full Year of 2023IIOT-OXYS, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2022, first quarter and full year of 2023. As predicted, the fourth quarter revenue exceeded that in the third quarter. Overall, 2022 annual revenue exceeded that of 2020 and 2021 combined.This first quarter of 2023 is already on track to exceed the fourth quarter revenue in 2022. Overall, The company expects 2023 revenue to exceed that in 2022.
공시 • Dec 06IIOT-OXYS, Inc. announced that it has received $0.061 million in fundingOn December 5, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. J.H. Darbie & Co., Inc. acted as a finder in the transaction. The company has paid $1,220 as finder fee in the transaction.
공시 • Nov 25IIOT-OXYS, Inc. Provides Revenue Guidance for the Second Half and Full Year 2022IIOT-OXYS, Inc. provided revenue guidance for the second half and full year 2022. The company expected revenue for the second half of 2022 will exceed that generated in the first half of 2022.In total, the company expected that total revenue for 2022 will be approaching 2019 levels.
공시 • Jul 13IIOT-OXYS, Inc. announced that it has received $0.027273 million in fundingOn July 12, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $546 to the finder J.H. Darbie & Co.
공시 • Jun 24IIOT-OXYS, Inc. announced that it has received $0.030144 million in fundingOn June 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $603 to the finder J.H. Darbie & Co.
공시 • Jun 09+ 2 more updatesIIOT-OXYS, Inc. Announces CFO ChangesIIOT-OXYS, Inc. announced that on June 2, 2022, Clifford L. Emmons resigned as Interim Chief Financial Officer and, on the same date, Karen McNemar, age 53, was appointed as the Interim Chief Financial Officer (Principal Financial and Accounting Officer) of the Company. Except as mentioned herein, there are no other arrangements or understandings between Ms. McNemar and any other persons pursuant to which Ms. McNemar was selected in the officer position above. There are no family relationships between Ms. McNemar and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. Ms. McNemar has served as Chief Operating Officer since September 20, 2018. From 1998 until August 2017, Ms. McNemar served in many capacities for Medtronic which included as a Senior Director of R&D Operations. Ms. McNemar is a collaborative strategic global business leader with extensive experience in New Product Development and Operations, building strong and effective diverse teams across organizations at all levels. Ms. McNemar is also a trusted advisor, recognized for successful process and program management, with a focus on leading complex initiatives and analyzing data and processes to identify solutions to increase organizational productivity and performance. Ms. McNemar received her Bachelor of Science in Industrial Engineering and Operations Research.
공시 • May 24IIOT-OXYS, Inc. announced that it has received $0.043096 million in fundingOn May 23, 2022, IIOT-OXYS, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $4,310 to the finder J.H. Darbie & Co.
공시 • Apr 01IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2022, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Feb 26IIOT-OXYS, Inc. announced that it has received $0.051 million in fundingOn February 24, 2022, IIOT-OXYS, Inc. closed the transaction. The company has received funding from one investor.
공시 • Apr 02IIOT-OXYS, Inc. announced delayed annual 10-K filingOn 03/31/2021, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Mar 18IIOT-OXYS, Inc. Appoints Chandran Seshagiri as Company's Advisory Board ChairmanIIOT-OXYS, Inc. announced the appointment of Chandran Seshagiri as the company's Advisory Board Chairman. Chandran is uniquely qualified to lead company Advisory Board, as he has made significant contributions to company past successful projects and continues to lead company algorithm development efforts on current and future projects. His passion for transforming complex signals into actionable information began with his work at the Harvard-MIT Division of Health Sciences and Technology, where he completed his Ph.D. Chandran's work analyzing physiological time series signals to enable personalized delivery of anesthesia as well as neurostimulation therapy has translated well to the time series data and predictive analyses required for Smart Manufacturing and Structural Health Monitoring applications for IIOT-OXYS, Inc.'s customers.
공시 • Sep 28IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc.IIOT-OXYS, Inc. (OTCPK:ITOX) entered into a letter of intent to acquire Infinite Automation Systems, Inc. on September 26, 2019. The closing of the transaction is subject to a number of conditions precedent, including satisfactory due diligence and the execution of definitive agreements, including employment agreements with the principal officers and directors of Infinite Automation Systems.
공시 • Sep 26IIOT-OXYS, Inc. announced that it expects to receive $0.5 million in funding from Catalytic Capital, LLC and another investorIIOT-OXYS, Inc. (OTCPK:ITOX) announced that it has entered into a securities purchased agreement for the private placement of 12% senior secured convertible notes for gross proceeds of $500,000 on March 6, 2019. The note is convertible, in whole or in part, into common shares at a conversion price of $0.20 per share. The note bears interest at a rate of 12% per annum payable quarterly. The will note matures on March 1, 2021. The notes will be issued in 3 tranches of $100,000 and last tranche of $200,000. The company will issue warrants to purchase one share of the company for 50% of the number of shares of shares issuable upon conversion of the note. Each warrant is immediately exercisable at $0.30 per share and expires five years from the issuance date. The notes will be issued pursuant to exemption provided under Regulation D. On the same date, the company has received $100,000 from Catalytic Capital, LLC and YVSGRAMORAH LLC for $50,000 each in its first tranche. The company also issued 250,000 warrants in the tranche.
공시 • Aug 18IIOT-OXYS, Inc. announced delayed 10-Q filingOn 08/17/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 30IIOT-OXYS, Inc. announced delayed 10-Q filingOn 06/29/2020, IIOT-OXYS, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.